The effect of erythropoietin on chloride levels during hypoxia reoxygenation injury in rats

Objective. This experimental study examined the effect of erythropoietin (Epo) in a rat model and particularly in a hypoxiareoxygenation (HR) protocol. The effect of that molecule was studied biochemically using blood mean chloride (Cl) levels. Materials and methods. 40 rats of mean weight 247.7 g were used in the study. Cl levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of reoxygenation. Erythropoietin was administered only in groups C and D. Results. Epo administration non-significantly decreased Cl levels by 1.07%+0.91% (p=0.2635). Reoxygenation time nonsignificantly decreased Cl levels by 0.68%+0.92% (P= 0.4457). However, erythropoietin administration and reoxygenation time together produced a non-significant combined effect in decreasing Cl levels by 0.74%+0.54% (P= 0.1701). Conclusions. Epo administration, reoxygenation time and their interaction have non-significant, short-term, decreasing effects on Cl levels

The trends of the antioxidant drug “U-74389G” on potassium levels during hypoxia reoxygenation injury in rats

Background: This experimental study examined the trends of the antioxidant drug “U-74389G”, on a rat model and particularly in a hypoxia – reoxygenation (HR) protocol. The trends of that molecule were studied biochemically using blood mean potassium levels. Methods: 40 rats of mean weight 231.875 g were used in the study. Potassium (K+) levels were measured at 60 min of reoxygenation (groups A and C) and at 120 min of reoxygenation (groups B and D) with administration of the drug U-74389G in groups C and D. Results: U-74389G administration non significantly decreased the K+ levels by 2.14%+5.06% (p= 0.6730). Reoxygenation time non-significantly increased the K+ levels by 8.66%+4.85% (p= 0.0934). However, U-74389G administration and reoxygenation time together non-significantly increased the K+ levels by 2.07%+3.03% (P= 0.4853). Conclusions: U-74389G administration, reoxygenation time and their interaction have miscellaneous non significant short – term trends on potassium levels. Perhaps, a longer study time or a higher drug dose may reveal clearer and significant effects

The effect of the antioxidant drug “U-74389G†on creatine kinase - MB levels during ischemia reperfusion injury in rats

Background: This experimental study examined the effect of the antioxidant drug “U-74389Gâ€, on a rat model and particularly in a liver ischemia - reperfusion protocol. The effects of that molecule were studied biochemically using blood mean creatine kinase - MB (CK-MB) levels. Methods: 40 rats of mean weight 231.875 g were used in the study. CK-MB levels were measured at 60 min of reperfusion (groups A and C) and at 120 min of reperfusion (groups B and D). The drug U-74389G was administered only in groups C and D. Results: U-74389G administration kept significantly increased the CK-MB levels by 31.60% + 13.10% (p = 0.0148). Reperfusion time kept non-significantly increased the CK-MB levels by 5.40% + 14.09% (p= 0.6358). However, U-74389G administration and reperfusion time together kept non-significantly increased the CK-MB levels by 14.50% + 8.16% (p=0.0745). Conclusions: U-74389G administration reduced at non-significantly increased the CK-MB levels, getting on decline them from significant to non-significant level

The acute effect of the antioxidant drug “U-74389G†on mean corpuscular volume levels during hypoxia reoxygenation injury in rats

Background: This experimental study examined the effect of the antioxidant drug “U-74389Gâ€, on a rat model and particularly in a hypoxia – reoxygenation (HR) protocol. The effects of that molecule were studied hematologically using mean blood corpuscular volume (MCV) levels.Methods: 40 rats of mean weight 231.875 g were used in the study. MCV levels were measured at 60 min of reoxygenation (groups A and C) and at 120 min of reoxygenation (groups B and D) with administration of the drug U-74389G in groups C and D.Results: U-74389G administration significantly increased the predicted MCV levels by 2.88%+0.69 (p= 0.0002). Reoxygenation time non-significantly increased the MCV levels by 0.57%+0.83% (p=0.4103). However, U-74389G administration and reoxygenation time together significantly increased the MCV levels by 1.60%+0.43% (p= 0.0005).Conclusions: U-74389G administration whether it interacted or not with reoxygenation time has significant increasing short – term effect on recovery pathophysiology of MCV values

The effect of erythropoietin on calcium levels during hypoxia reoxygenation injury in rats

This experimental study examined the effect of erythropoietin (Epo) on rat model and particularly in a hypoxia-reoxygenation protocol. The effect of that molecule was studied biochemically using blood mean calcium levels (Ca++). Forty rats of mean weight 247.7 g were used in the study. Ca++ levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of reoxygenation. Erythropoietin was administered only in groups C and D. Epo administration non-significantly decreased the Ca++ levels by 0.56%±1.13% (P=0.5761). Reoxygenation time non-significantly increased the Ca++ levels by 0.65%±1.12% (P=0.5281). However, Epo administration and reoxygenation time together non-significantly decreased the Ca++ levels by 0.34%±0.68% (P=0.6095). Epo administration whether it interacted or not with reoxygenation time had non-significant decreasing short-term effects on calcium levels. Perhaps, a longer study time than 2 h or a higher Epo dose may reveal more significant effects

The Effect of the Antioxidant Drug U-74389G on Uric Acid Levels during Ischemia Reperfusion Injury in Rats

This experimental study examined the effect of the anti-oxidant drug U-74389G in a rat model using a renal ischaemia-reperfusion (IR) protocol. The effects of the molecule were studied biochemically by assessing mean serum uric acid levels (SUA). In total, 40 rats (mean weight = 231.875 g) were used in the study. SUA levels were measured at 60 min of reperfusion for groups A and C and at 120 min of reperfusion for groups B and D. The drug U-74389G was administered only in groups C and D. U-74389G administration non-significantly increased the SUA levels by 15.43%±9.10% (p=0.096) at the representative endpoint of 1.5 h. The reperfusion time non-significantly decreased the SUA levels by 13.61%±9.18% (p=0.126). However, the interaction of U-74389G administration and reperfusion time non-significantly increased the SUA levels by 4.78%±5.64% (p= 0.387). Whether it interacted with the reperfusion time, U-74389G administration non-significantly increased SUA levels. It seems that U-74389G cannot reverse injury to IR tubular epithelial cells within 2 hours

Acute effect of the antioxidant drug U-74389G on hematocrit levels during hypoxia and reoxygenation injury in rats

Aims: This experimental study evaluated the effect of the antioxidant drug U-74389G on hematocrit levels using a rat model of hypoxia and reoxygenation following an established protocol. Methods: Forty rats with a mean weight of 231.875 g were employed in the study. Hematocrit levels were determined at 60 min (groups A and C) and at 120 min (groups B and D) after starting reoxygenation. Groups A and B received no drugs, whereas U-74389G was administered to rats from groups C and D. Results: U-74389G administration significantly increased hematocrit levels by 4.73%±2.25% (p=0.0435). Reoxygenation time increased hematocrit levels non significantly by 3.96%±2.29% (p=0.1025). U-74389G administration combined with reoxygenation time significantly increased hematocrit levels by 3.16%±1.33% (p=0.0196). Conclusions: U-74389G administration, whether it interacted or not with reoxygenation time, significantly increased hematocrit levels in the short term in a rat model of hypoxia and reoxygenation

Acute effect of the antioxidant drug U-74389G on hematocrit levels during hypoxia and reoxygenation injury in rats = Efeito agudo do fármaco antioxidante U-74389G sobre os níveis de hematócrito durante a lesão induzida por hipóxia e reoxigenação em ratos

Objetivos: Este estudo experimental avaliou o efeito da droga antioxidante U-74389G nos níveis de hematócrito, utilizando um modelo murino de hipóxia e reoxigenação, de acordo com um protocolo estabelecido. Métodos: Quarenta ratos com um peso médio de 231,875 g foram utilizados no estudo. Os níveis de hematócrito foram determinados aos 60 min (grupos A e C) e aos 120 minutos (grupos B e D) após o início da reoxigenação. Os grupos A e B não receberam nenhuma droga, enquanto que a U-74389G foi administrada aos ratos dos Grupos C e D. Resultados: A administração de U-74389G aumentou significativamente os níveis de hematócrito em 4,73%±2,25% (p=0,0435). O tempo de reoxigenação aumentou não significativamente os níveis de hematócrito em 3,96%±2,29% (p=0,1025). Aadministração de U-74389G combinada com o tempo de reoxigenação aumentou significativamente os níveis de hematócrito em 3,16%±1,33 (p=0,0196). Conclusões: A administração de U-74389G, quer interagindo ou não com o tempo de reoxigenação, aumentou significativamente, no curto prazo, os níveis de hematócrito em um modelo murino de hipóxia e reoxigenaçã

The Acute Effect of Erythropoietin on Mean Platelet Volume Levels during Hypoxia Reoxygenation Injury in Rats

Aim: This biomedical study tested the effect of erythropoietin (Epo) in rat model, especially in a hypoxia-reoxygenation one. The trend of this factor was evaluated hematologically using serum mean platelets volume (MPV) values. Methods: Forty rats with a mean mass 247.7 g were used. MPV values were evaluated at 60 min (for groups A and C) and at 120 min (for groups B and D) of reoxygenation. Epo was provided only in groups C and D. Results: Epo administration non-significantly lowered the MPV levels by 0.12% +2.13% (p=0.9513). Reoxygenation time non-significantly augmented the MPV levels by 1.37%+2.11% (p=0.4873). However, Epo administration together with reoxygenation time non-significantly reduced the MPV levels by 0.27%+0.92% (p=0.7585). Conclusion: Epo administration had a non-significant short-time decline effect on MPV levels